id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zsDo2rQ_Eem6W88t2VAOtw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"bladder cancer cell lines were responsive to IL-17, as demonstrated by increased production of IL-6 and IL-8 ", same level (Fig 3B). All three ,"(Fig 3C and 3D). However, subseq",TextQuoteSelector,TextPositionSelector,24934,25043,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:36:15.418831+00:00
ySve7q07EemaNePa3fbzGA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumours, IL-17+ cells were from grade 3 ,"; however, not all grade 3 tumou",TextQuoteSelector,TextPositionSelector,21417,21424,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:19:49.672003+00:00
vmuPlLQ_EemziFur0t_6Dg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 on three bladder cancer,e examined the direct effect of ," cell lines (EJ, 5637 and HB-CLS",TextQuoteSelector,TextPositionSelector,24801,24830,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:47.750196+00:00
ufXImq07EemyBx_9fWnXZw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17,n the surrounding tumour stroma.,+ cells are increased in carcino,TextQuoteSelector,TextPositionSelector,20983,20988,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:19:24.285402+00:00
uRaHuq08Eem4aX_b7cDT7w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,growth factor,S1 File). Genes associated with , activity were increased and sig,TextQuoteSelector,TextPositionSelector,29378,29391,WT_GP,no,[WT_GP],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:26:32.348041+00:00
uPzbfq0-EemJkquA5HmvIw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,reverse transcriptase,f primers used for quantitative , PCR.(DOCX)Click here for additi,TextQuoteSelector,TextPositionSelector,46093,46114,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:40:51.082430+00:00
uIZQvrQ_Eem8wX_wW1z9Zg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 on bladder tumours,etermine the effect of elevated ,". First, we stained 14 bladder c",TextQuoteSelector,TextPositionSelector,24420,24444,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:38.101047+00:00
tfrP0q03EembPsN3jKV86g,b53nbDmi,https://europepmc.org/articles/PMC5607173/,UBC ,chanism of BCG immunotherapy in ,and could form the basis of a st,TextQuoteSelector,TextPositionSelector,11995,11999,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:50:39.745157+00:00
tWdxBrQ_Eemz_e-yYzbWBw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 has been reported to act directly on tumour,evated numbers of IL-17+ cells. , and stromal cells that express ,TextQuoteSelector,TextPositionSelector,24092,24141,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:32.785716+00:00
t-2zFq05EemmTltQFjJTXQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,Bacillus Calmette-Guerin,repeated cycles of intravesical , (BCG) immunotherapy in a regime,TextQuoteSelector,TextPositionSelector,13244,13268,CRT_OG,no,CRT_OG,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:05:01.775324+00:00
sNYlfrQ_EemLLveqchV7CA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 on bladder cancer,"cells [27,28].Direct effects of ", cells in vitroWe next considere,TextQuoteSelector,TextPositionSelector,23960,23983,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:24.891480+00:00
r_HnEq06Eem-T1OHDmEbiA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 receptor,).Open in a separate windowFig 3, expression and function in blad,TextQuoteSelector,TextPositionSelector,25751,25765,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:11:57.955557+00:00
rS4HxLRAEem0A6s_icRtow,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17-positive cells were significantly increased in primary and concomitant carcinoma,p for 4.33Â±1.71 years. We found ," in situ (CIS), p<0.0001, a high",TextQuoteSelector,TextPositionSelector,10907,10993,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:42:28.475906+00:00
ql6YyrQ_EemSwo-_MZrhgQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"tumour and stromal cells were present in excess, we detected increased IL-17 ",r microenvironment. Even though ,mRNA transcripts in samples from,TextQuoteSelector,TextPositionSelector,23349,23426,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:14.090497+00:00
pbSM-LQ_EemGoQcpN63-yw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 positive cells present in different bladder cancer,age.Upper panels: The number of , biopsies are displayed accordin,TextQuoteSelector,TextPositionSelector,21911,21967,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:35:06.406920+00:00
p7B1Lq05EemTEA_rQZP-Tg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,dysplasia,(CIS) [8]. This flat high-grade , is highly malignant with signif,TextQuoteSelector,TextPositionSelector,13044,13053,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:04:34.608836+00:00
oH-jPq09EemsK-foRni01g,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17R,tly upon tumour cells that bear , [42]. Since we found that IL-17,TextQuoteSelector,TextPositionSelector,38151,38157,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:33:00.428906+00:00
oEmGGrQ_Eemifu_oyQVkuA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 positive cells and bladder cancer, windowFig 2Association between , grade and stage.Upper panels: T,TextQuoteSelector,TextPositionSelector,21827,21866,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:57.400054+00:00
na5TtK07EemfkQs3D38P-w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CD4,"uted to Th17 cells, a subset of ","+ T cells, although other immune",TextQuoteSelector,TextPositionSelector,20316,20319,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:18:36.762822+00:00
na1UfK03EemZgO8wySGznA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder CIS,"action. Thus, in the context of ",", IL-17+ mast cells predict favo",TextQuoteSelector,TextPositionSelector,11853,11864,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:49:58.899907+00:00
n20FBLRAEemQh-8UxHocnQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 staining into standard histopathological tumour , in UBC patients. Incorporating ,"assessment, or potentially inclu",TextQuoteSelector,TextPositionSelector,44595,44649,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:42:05.536266+00:00
mlTFlLQ_EemNYys_l3aNSA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumours at time of diagnosis demonstrated that there was a significant increase in IL-17,2A). Examining the stage of the ,+ cells in CIS patients (p = <0.,TextQuoteSelector,TextPositionSelector,21574,21662,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:47.458153+00:00
mcwDtrRAEemIJrsiu_4vXA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"IL-17, inducing IL-8 production by urothelium and, as we have shown, tumour",cited via MCs rapidly releasing , cells recruiting increased numb,TextQuoteSelector,TextPositionSelector,43005,43080,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:41:55.925610+00:00
ls74mrQ_Eem63-vId5k_7A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cells were from grade 3 tumours,sample with elevated numbers of ,"; however, not all grade 3 tumou",TextQuoteSelector,TextPositionSelector,21427,21465,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:41.305809+00:00
loKnUK09EemP418I6WHtvw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bear,directly upon tumour cells that , IL-17R [42]. Since we found tha,TextQuoteSelector,TextPositionSelector,38146,38150,WT_OG,no,[WT_OG],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:32:43.692024+00:00
lbjd8K07EemfkAsU3mZQGA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,cytokine, A.An antibody specific for the , IL-17 was included in our panel,TextQuoteSelector,TextPositionSelector,20212,20220,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:18:23.612856+00:00
kaKNrrRAEemQXg8PjTZV4Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"IL-17 in place of murine MCs [19]; consistently, Î³Î´T cells produce IL-17 in response to BCG in a murine model of bladder cancer ",udies suggest Î³Î´T cells produce ,"[25]. In this model, IL-17 was r",TextQuoteSelector,TextPositionSelector,42422,42550,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:41:42.324120+00:00
kCNLBLQ_EemqpwOO1cyAJw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cell infiltrate led us to stain more tumour,es observed in the frequency of , specimens (n = 48). All biopsy ,TextQuoteSelector,TextPositionSelector,21123,21173,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:30.150559+00:00
jSWJ9q05Eemo-RPn5orD3A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,MIBC,muscle-invasive bladder cancer (,: stages T2+) occurs in up to 45,TextQuoteSelector,TextPositionSelector,12636,12640,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:03:50.101285+00:00
iUTaaK09EempDjdv2E5sQA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,mice,r is complex. In IL-17 knockout ," some tumours grow more rapidly,",TextQuoteSelector,TextPositionSelector,37608,37612,CRT_OG,yes,[CRT_OG][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:32:21.439885+00:00
i44-Gq07EemSFS9PEzdrBA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CD68,"ins CD3+ T cells, FoxP3+ cells, ",+ macrophages and CD15+ granuloc,TextQuoteSelector,TextPositionSelector,19935,19939,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:18:06.328660+00:00
i21S0LQ_EemgJo8OMxtVDA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cells are increased in carcinoma,n the surrounding tumour stroma., in situThe marked differences o,TextQuoteSelector,TextPositionSelector,21024,21063,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:22.316908+00:00
hTNBoq05EemwQNMjEreBTg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,muscle-invasive bladder cancer,of patients [4]. Progression to , (MIBC: stages T2+) occurs in up,TextQuoteSelector,TextPositionSelector,12604,12634,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:03:36.909924+00:00
hAWZJrQ_EemkNENjEfMM2A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 positive (IL-17+) cells in different tumour,ere was noticeable variation in ," biopsies. When present, the maj",TextQuoteSelector,TextPositionSelector,20781,20830,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:09.906801+00:00
h2ZFhLQ_EemmYbeoPyPrvA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cells did not infiltrate into the tumour,". When present, the majority of ", but were located in the tumour ,TextQuoteSelector,TextPositionSelector,20871,20918,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:15.436348+00:00
gvuy9q06EemTElMoijUI5A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17A,ar intervals. Recombinant human ," (Peprotech, UK) was added as de",TextQuoteSelector,TextPositionSelector,16582,16588,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:10:42.563904+00:00
gvukrLRAEemknMt2pVEc8A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"cancer [44]; one possibility, therefore, is that BCG amplifies the beneficial effects associated with increased numbers of IL-17",l advantage seen in oesophageal ,"+ MCs.Currently, we can only spe",TextQuoteSelector,TextPositionSelector,40765,40893,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:41:17.805020+00:00
gIeZiK09EemtEnPYqQyjPw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumorigenesis,"31,32]. Conversely, MCs enhance "," and angiogenesis [33â35], and h",TextQuoteSelector,TextPositionSelector,37436,37449,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:32:07.057072+00:00
fuV_GrQ_EembYuOaZLZhBQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 has been implicated in the response to BCG immunotherapy in a murine bladder cancer ,on the disease setting [20â24]. ,"model [25]; however, there are n",TextQuoteSelector,TextPositionSelector,20552,20642,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:34:01.237754+00:00
fNePOq0_Eem3AWe_Chk2DA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,Human,listed in Table C in S2 File. A , Genome U133 Plus 2.0 Array (Aff,TextQuoteSelector,TextPositionSelector,17910,17915,WT_OG,no,[WT_OG],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:46:19.872877+00:00
fIRXwrRAEem8yN-nuzUJEw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ MCs at sites of active inflammation,muli. Reports have demonstrated , in rheumatoid arthritis [45â47],TextQuoteSelector,TextPositionSelector,41202,41244,AMB,no,AMB,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:41:06.765290+00:00
e6Albq06EemnulO7FkUtSA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,human, regular intervals. Recombinant ," IL-17A (Peprotech, UK) was adde",TextQuoteSelector,TextPositionSelector,16576,16581,CRT_OG,yes,[CRT_OG][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:10:29.896014+00:00
e-uYxq08EemorIPXpXtMGg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-8,ncreased production of IL-6 and ," (Fig 3C and 3D). However, subse",TextQuoteSelector,TextPositionSelector,24997,25001,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:24:49.699245+00:00
duK-jq05EemaLgf0jp6Ueg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,NMIBC,muscle invasive bladder cancer (,: stages Ta/T1/Tis) [3]. Patient,TextQuoteSelector,TextPositionSelector,12404,12409,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:03:12.779089+00:00
dUIZCrQ_EemeVIOz2BEgTw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"bladder cancer microenvironment contains CD3+ T cells, FoxP3+ cells, CD68+ macrophages and CD15+ granulocytes. B: Representative images from two bladder cancer biopsies with high (left) or low (right) numbers of IL-17",or the primary antibody. A: The , positive cells present. Note th,TextQuoteSelector,TextPositionSelector,19907,20124,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:33:45.155854+00:00
dJSsKq03Eem4TUuvEMIOzw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder tumours,ession of the IL-17-receptor in ,", and functional effects and gen",TextQuoteSelector,TextPositionSelector,11282,11297,WS_DS,yes,[WS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:48:50.002496+00:00
chnzqrRAEemFvJuhtZCDUQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ MCs in patients by utilising the long-term outcome data linked to the tumour,to identify the consequences of , samples. We acknowledge that su,TextQuoteSelector,TextPositionSelector,39584,39667,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:40:49.363367+00:00
bjiCUrQ_EemLLMeLdX4C3A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"IL-17-receptor in bladder tumours, and functional effects and gene expression changes induced by IL-17 in bladder tumour",tumour types. Expression of the , cells in vitro suggest a role i,TextQuoteSelector,TextPositionSelector,11305,11425,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:33:33.166578+00:00
afpWyK0-Eemo9VvUSurgiw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,cytokines,ed on changes in levels of nine ,", correctly identified 85.5% of ",TextQuoteSelector,TextPositionSelector,43438,43447,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:38:38.622733+00:00
aZz8wrRAEemkYmvOSkOAyA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"bladder cancer cell lines that we studied was not significantly affected by IL-17, despite eliciting a response by increased production of IL-6 and IL-8","ntrast, growth of the other two ",. Gene expression analysis revea,TextQuoteSelector,TextPositionSelector,39066,39218,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:40:34.801110+00:00
aVpqJLRAEema8Xt-v0A2ig,b53nbDmi,https://europepmc.org/articles/PMC5607173/," IL-17 vary markedly, even within the context of a single tumour",trate that the direct effects of, type.Although these in vitro ef,TextQuoteSelector,TextPositionSelector,39422,39486,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:40:34.794859+00:00
aI_FzLQ_EemLK7fQMvdE5Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumour immunophenotype identified IL-17,Further characterisation of the ,+ cells as predominantly mast ce,TextQuoteSelector,TextPositionSelector,11151,11190,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:33:23.644331+00:00
_r3L4K06EemyBNc0ooNUJw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 receptor,col. Cell surface levels of the , (IL-17R) were measured by flow ,TextQuoteSelector,TextPositionSelector,17462,17476,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:14:10.150999+00:00
_EoUiq07Eem6MTcJdCVVxQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-6,"of (C) IL-17A, (D) IL-17-F, (E) ", or (F) IL-23 are shown relative,TextQuoteSelector,TextPositionSelector,22462,22466,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:21:15.623449+00:00
ZI3eSK0_Eem3APuiV209-Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,Infiltrates,is analysis are shown in Fig 1. , of CD3+ T-cells were mostly pre,TextQuoteSelector,TextPositionSelector,18826,18837,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:45:39.113013+00:00
XtetJq06Eem4WQuVct66xQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,mycoplasma,0.1 mg/ml streptomycin (Sigma); , testing was carried out on rece,TextQuoteSelector,TextPositionSelector,16492,16502,"WT_DS,OG",no,[WT_DS][OG],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:09:41.806163+00:00
XlNJnK05EemaLXutXr12YA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,non-muscle invasive bladder cancer, patients (75â85%) present with , (NMIBC: stages Ta/T1/Tis) [3]. ,TextQuoteSelector,TextPositionSelector,12368,12402,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:02:31.475220+00:00
XNxsEK0-Eem6NROgGWYRzg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,humans,pose an alternative scenario in ,. We suggest that the immediate ,TextQuoteSelector,TextPositionSelector,42872,42878,CRT_OG,no,CRT_OG,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:38:16.658116+00:00
Wa_dhLRAEemjIesfsaRZXQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"tumours, we decided to focus on the potential direct effects of IL-17",R was expressed by many bladder , on bladder cancer cells. IL-17 ,TextQuoteSelector,TextPositionSelector,38262,38331,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:40:08.513134+00:00
W_BhSrRAEem5rVt91tkEBQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"IL-17 increased the growth rate of 5637 cells, concurring with previously published work examining the MB49 murine bladder cancer ",ession in different cell lines. ,"cell in mice [42]. Furthermore, ",TextQuoteSelector,TextPositionSelector,38490,38620,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:40:12.037482+00:00
WQ8RuK06EemwnE-dD_5QWA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bovine,um supplemented with 10% foetal ," serum, 100 U/ml penicillin and ",TextQuoteSelector,TextPositionSelector,16422,16428,WT_OG,no,[WT_OG],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:09:32.302701+00:00
WBnELK03Eem6JtPGIcqpzA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17-receptor,tumour types. Expression of the ," in bladder tumours, and functio",TextQuoteSelector,TextPositionSelector,11264,11278,WS_GP,yes,[WS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:48:02.227319+00:00
V_NAoK07Eem4UC-3RUufHA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CD15,"s) and innate (TCRÎ³, Î³Î´T cells; ",", granulocytes; CD68, macrophage",TextQuoteSelector,TextPositionSelector,18708,18712,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:16:39.899015+00:00
Tsaorq08EemUJFNB_3CgKw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17F, levels of the related cytokine ," as well as IL-6, the expression",TextQuoteSelector,TextPositionSelector,23655,23661,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:23:33.745286+00:00
TD-H0LRAEemSxHOIdr_1Sw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 knockout mice some tumours, IL-17 in cancer is complex. In ," grow more rapidly, whilst other",TextQuoteSelector,TextPositionSelector,37634,37666,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:45.618235+00:00
T6Xg_rRAEemQhGtxMMaaCQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"IL-17 can act indirectly (for example, promoting tumour",ome in the UBC setting.Although , growth by altering the immune m,TextQuoteSelector,TextPositionSelector,38029,38084,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:51.590812+00:00
SpUSyK0-EemXtQtzOYYL6Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,mouse,red by a lack of a suitable CIS ," model [51,52], and fundamental ",TextQuoteSelector,TextPositionSelector,42069,42074,CRT_OG,yes,[CRT_OG][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:37:45.969243+00:00
Se_r4q03EemUGAufjjTLyw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,carcinoma in situ,ased in primary and concomitant ," (CIS), p<0.0001, a highly malig",TextQuoteSelector,TextPositionSelector,10943,10960,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:47:38.351017+00:00
SFABQq07EemVU0fSPJXklg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,TCRÎ³,regulatory T cells) and innate (,", Î³Î´T cells; CD15, granulocytes;",TextQuoteSelector,TextPositionSelector,18691,18695,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:16:13.459135+00:00
SEV0qrRAEemqq09nMZu6cQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 in cancer," [36,37]. Likewise, the role of ", is complex. In IL-17 knockout m,TextQuoteSelector,TextPositionSelector,37603,37618,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:39.025453+00:00
QbrEVK0-EemQ4MvcofIkpg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,toll-like receptor-2,hown to produce IL-17 following , ligation [50].Deeper understand,TextQuoteSelector,TextPositionSelector,41873,41893,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:37:31.173580+00:00
QRfhlq03EemTCv8iyeyrzg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17,p for 4.33Â±1.71 years. We found ,-positive cells were significant,TextQuoteSelector,TextPositionSelector,10866,10871,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:47:23.393639+00:00
QBDomK07EemmV6Pxt2qfEg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,FoxP3,"of the adaptive, (CD3, T cells; ",", regulatory T cells) and innate",TextQuoteSelector,TextPositionSelector,18652,18657,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:15:59.897074+00:00
Pa1znq09EemwqCOUYkx00g,b53nbDmi,https://europepmc.org/articles/PMC5607173/,ELANE,pecific markers of neutrophils (,") or MCs (mast cell tryptase, MC",TextQuoteSelector,TextPositionSelector,31021,31026,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:30:14.876239+00:00
PR1lQrRAEemtRO-PNrmuSw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"tumour, the IL-17",ncy and distribution within the ,+ cells were clearly not T cells,TextQuoteSelector,TextPositionSelector,36946,36963,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:20.463575+00:00
OuIq2q07EemSEncc-NHj3g,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CD3,"c for markers of the adaptive, (",", T cells; FoxP3, regulatory T c",TextQuoteSelector,TextPositionSelector,18638,18641,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:15:50.943696+00:00
OhMdhK08Eem67YP3p3JHLw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,GAPDH,o GAPDH (ÎCT = CTExperimental-CT,). Asterisks indicate significan,TextQuoteSelector,TextPositionSelector,22532,22537,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:22:58.974818+00:00
Oh1ZkrRAEemjIGv5-WEUUg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cells in their tumours, some patients with CIS had few ,", suggesting their presence was ",TextQuoteSelector,TextPositionSelector,36704,36733,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:15.547139+00:00
NPHwhrRAEemtQ4Nihkia0Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17+ cells between different patientsâ tumours,ked variation in the numbers of ,", with increased numbers of thes",TextQuoteSelector,TextPositionSelector,36519,36567,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:39:06.616063+00:00
NKyRNq03EemonuP1AWQzQg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder cancer,entre cohort of newly-diagnosed ," patients, followed-up for 4.33Â±",TextQuoteSelector,TextPositionSelector,10799,10813,WS_DS,yes,[WS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:47:02.555899+00:00
MG1LJq06EemyAq92J7F0ig,b53nbDmi,https://europepmc.org/articles/PMC5607173/,breast cancer,", University of Birmingham. The ", cell line MDA-MB-231 was provid,TextQuoteSelector,TextPositionSelector,16257,16270,WS_DS,yes,[WS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:08:23.941423+00:00
LyMjlrRAEemtQgOsgV7now,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 has been implicated in the efficacy of BCG immunotherapy in a murine bladder cancer ,"he remainder (Fig 5A). However, ",model [25]; although patients wi,TextQuoteSelector,TextPositionSelector,34390,34480,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:38:56.882878+00:00
LKpldK0-Eemosmf0YzWjog,b53nbDmi,https://europepmc.org/articles/PMC5607173/,psoriasis,"n rheumatoid arthritis [45â47], ", [48] and atherosclerotic plaque,TextQuoteSelector,TextPositionSelector,41237,41246,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:36:55.633423+00:00
Ks9qKrRAEemQXLe5Su1sIQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/, tumour specimen stained for IL-17 ,s a serial section from the same,alone (red) for comparison. The ,TextQuoteSelector,TextPositionSelector,33596,33631,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:38:49.868311+00:00
JnxCYq0-EemmUlckIuh8Og,b53nbDmi,https://europepmc.org/articles/PMC5607173/,rheumatoid arthritis,sites of active inflammation in ," [45â47], psoriasis [48] and ath",TextQuoteSelector,TextPositionSelector,41207,41227,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:36:45.211256+00:00
JPngHLRAEemLnf8F6BzOcw,b53nbDmi,https://europepmc.org/articles/PMC5607173/, IL-17 were observed in all cases confirming that MCs are the main source of IL-17 in the tumour, cells positive for both MCT and, microenvironment of bladder CIS,TextQuoteSelector,TextPositionSelector,31899,31995,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:38:39.750802+00:00
HxolNq08EemimzMgRQxZXw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,GAPDH,(F) IL-23 are shown relative to , (ÎCT = CTExperimental-CTGAPDH).,TextQuoteSelector,TextPositionSelector,22502,22507,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:22:13.959515+00:00
Hg4scrRAEem8w-vzkmNNvA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,inflammatory response and cell adhesion were downregulated by IL-17,"contrast, genes involved in the ", treatment.Mast cells constitute,TextQuoteSelector,TextPositionSelector,29687,29754,AMB,no,AMB,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:38:28.422116+00:00
HcCguK06EemJhQvkkhVdmw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CLS,r cancer cell lines 5637 and HB-,-2 were obtained from the ATCC. ,TextQuoteSelector,TextPositionSelector,16149,16152,WT_GP,yes,[WT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:07:52.835615+00:00
Gs4i0K07EemaMxsHAz9CZQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17R,e levels of the IL-17 receptor (,) were measured by flow cytometr,TextQuoteSelector,TextPositionSelector,17478,17484,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:14:57.287824+00:00
GokDhK03Eem64r9oUCVmUA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder tumour,characterise and understand the , microenvironment of 114 patient,TextQuoteSelector,TextPositionSelector,10694,10708,WS_DS,yes,[WS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:46:18.781370+00:00
GoPdkK09Eem68wdPVhotaQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,MC tryptase,ins MCs that stain positive for , (MCT). No ELANE-positive neutro,TextQuoteSelector,TextPositionSelector,32885,32896,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:29:15.827453+00:00
Gai3SrRgEemb0YcxrMzEow,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumours,pes have been identified within ,", and the effects of a particula",TextQuoteSelector,TextPositionSelector,13923,13930,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T13:27:24.826250+00:00
Fy9Roq08Eem4Y_ua_k7oZA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17-F," transcripts of (C) IL-17A, (D) ",", (E) IL-6 or (F) IL-23 are show",TextQuoteSelector,TextPositionSelector,22449,22456,WS_GP,no,WS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:22:00.824885+00:00
F21FHq0-EemnT3MW82Qq6A,b53nbDmi,https://europepmc.org/articles/PMC5607173/,oesophageal cancer, the survival advantage seen in ," [44]; one possibility, therefor",TextQuoteSelector,TextPositionSelector,40712,40730,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:36:20.104113+00:00
EMX6UK03EemP4UPCWpxIhw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,cancer,ment is considered to influence , behaviour and outcome. Using a ,TextQuoteSelector,TextPositionSelector,10556,10562,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:46:02.498025+00:00
DEB0rq0-EemJkWtXtxTW-w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,oesophageal squamous cell carcinoma,-keeping with a recent study in , where IL-17+ MCs were also iden,TextQuoteSelector,TextPositionSelector,40336,40371,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:36:01.452106+00:00
D-UeiK06EemnRtOIUEJsSg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,alkaline phosphatase, in S2 File) and HRP-DAB and/or ,-vector red enzyme-substrate com,TextQuoteSelector,TextPositionSelector,15466,15486,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:07:29.407031+00:00
BHWcCrRAEemif9P-jxUudA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder cancer cell lines exposed to IL-17,henotype exhibited by different , led us to perform microarray an,TextQuoteSelector,TextPositionSelector,28053,28095,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:37:45.504464+00:00
B0-Ggq06Eemcf6MBafrp9w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,HRP,bodies (Table A in S2 File) and ,-DAB and/or alkaline phosphatase,TextQuoteSelector,TextPositionSelector,15451,15454,WT_GP,no,[WT_GP],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:07:15.179209+00:00
Auvukq0-Eem2_KtoFV-87w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,gastric cancer,ssociation recently observed in ," [23]. Paradoxically, CIS patien",TextQuoteSelector,TextPositionSelector,40077,40091,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:35:45.729293+00:00
AebZ-q03EemfgudsfJpobQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumour, are credited.Go to:AbstractThe , immune microenvironment is cons,TextQuoteSelector,TextPositionSelector,10498,10504,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:45:37.601231+00:00
A-3Diq08EemYXyuwgzpibA,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-23,"A, (D) IL-17-F, (E) IL-6 or (F) ", are shown relative to GAPDH (ÎC,TextQuoteSelector,TextPositionSelector,22474,22479,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:21:28.417172+00:00
9op_3rQ_Eemsj5PSxNa95w,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"bladder cancer biopsy, in this case CIS, stained with a primary antibody specific for the IL-17",sentative result obtained for a , receptor (brown staining repres,TextQuoteSelector,TextPositionSelector,25889,25984,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:37:22.163396+00:00
9550XK08Eem23vdQGUI82Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,MCT,"NE) or MCs (mast cell tryptase, ",). We saw little or no ELANE sta,TextQuoteSelector,TextPositionSelector,31056,31059,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:28:17.290243+00:00
8ashMLQ_EemkN_dBdp2_wQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,IL-17 receptor expression and function in bladder cancer,).Open in a separate windowFig 3,.A: Representative result obtain,TextQuoteSelector,TextPositionSelector,25792,25848,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:37:13.814787+00:00
8_SRmq05Eem4VntIyIs8Cw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,UBCs,ples of newly-diagnosed primary , were obtained from the Bladder ,TextQuoteSelector,TextPositionSelector,14747,14751,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:06:42.610691+00:00
8XdpSK09EemUfRewmS4V9g,b53nbDmi,https://europepmc.org/articles/PMC5607173/,tumour, within the context of a single , type.Although these in vitro ef,TextQuoteSelector,TextPositionSelector,39439,39445,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:35:16.171565+00:00
8UjJrq08EemP-U9xWubLdg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,mast cell tryptase, of neutrophils (ELANE) or MCs (,", MCT). We saw little or no ELAN",TextQuoteSelector,TextPositionSelector,31036,31054,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:28:06.653650+00:00
7XoFyK07EemkI_di3TMSFg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,pT1,"time of diagnosis (pTa, n = 17; ",", n = 10; T2+, n = 8; CIS, n = 8",TextQuoteSelector,TextPositionSelector,22077,22080,WT_GP,yes,[WT_GP][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:20:50.636712+00:00
6kkbtK02EemSAFe0zuuwjQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,urothelial bladder cancer, the immune microenvironment of ,"Alexander C. Dowell, Conceptuali",TextQuoteSelector,TextPositionSelector,6252,6277,WS_DS,yes,[WS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:44:57.896863+00:00
6OZhmrQ_EemwQxs4ETPcRQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"cancer cell lines showing IL-17 to enhance cell migration [24], as demonstrated by the breast cancer",trast to previous work on other , control cell line included in o,TextQuoteSelector,TextPositionSelector,25602,25702,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:36:59.065857+00:00
5btzWq0-EemYZocYyXwpxg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,Cancer, were obtained from the Bladder , Prognosis Programme (BCPPâclini,TextQuoteSelector,TextPositionSelector,14783,14789,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T11:42:06.057065+00:00
4L7YXq02EemonYdBbWRndw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,CIS,omes from BCG for patients with ,: Data from a comprehensive char,TextQuoteSelector,TextPositionSelector,6170,6173,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:44:41.886831+00:00
34WUSq03EemSAv9ivcHa6Q,b53nbDmi,https://europepmc.org/articles/PMC5607173/,transitional cell carcinoma,ions 90% of bladder cancers are , of urothelial origin (urothelia,TextQuoteSelector,TextPositionSelector,12246,12273,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:51:49.348999+00:00
2tu1Lq02EembOnudvnzTUQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,BCG,t cells influence outcomes from , for patients with CIS: Data fro,TextQuoteSelector,TextPositionSelector,6148,6151,MIS_OG,yes,[MIS_OG][ALL],,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:44:32.133285+00:00
1xgiqq03Eem6JyNkA3DMAQ,b53nbDmi,https://europepmc.org/articles/PMC5607173/,bladder cancers,. In Western populations 90% of , are transitional cell carcinoma,TextQuoteSelector,TextPositionSelector,12226,12241,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:51:35.305456+00:00
0joOhK02Eem4Si8cCjIEZw,b53nbDmi,https://europepmc.org/articles/PMC5607173/,Interleukin-17,1PMCID: PMC5607173PMID: 28931051,-positive mast cells influence o,TextQuoteSelector,TextPositionSelector,6089,6103,MIS_GP,no,MIS_GP,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-07-23T10:44:17.644850+00:00
-0N-SrQ_Eemkl6OjrmcnWg,b53nbDmi,https://europepmc.org/articles/PMC5607173/,"breast cancer cell line MBA-MD231, which is more invasive in response to IL-17",r 48 hours before wounding. The ,", was included as a positive con",TextQuoteSelector,TextPositionSelector,27269,27347,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.,2019-08-01T09:37:29.988586+00:00
